Karyopharm plans to merge with Ayrmid, the company that tried buying bluebird

With few options remaining, a commercial-stage blood cancer biotech will go through a bankruptcy process and plans to merge with another drugmaker in the blood disorder field. Karyopharm Therapeutics, maker of the multiple myeloma drug ...